Fig. 2From: Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failureKaplan–Meier analysis of patients’ overall survival. Clindamycin (C), clindamycin plus primaquine (C-P), clindamycin plus caspofungin (C-Ca), clindamycin plus primaquine plus caspofungin (C-P-Ca)Back to article page